Sugentech, Inc.
SUGENTECH is a leading company in the field of in vitro diagnostics, specializing in the development of next-generation diagnostic products by integrating bio, nano, IT, and AI technologies. The company aims to provide faster, more accurate, and user-friendly diagnostic solutions to improve health outcomes worldwide, with a focus on digital healthcare platforms and innovative diagnostic systems.
Industries
Nr. of Employees
medium (51-250)
Sugentech, Inc.
206, Techno 2-ro, Yuseong-gu, Daejeon, South Korea
Patents
Probe system for real-time quantitative and qualitative analysis of biomaterial, reaction chamber with said probe system, and analysis method thereof
US-10428372-B2
View DetailsMethod of quantitatively and qualitatively analyzing biomaterial in real-time
US-10364459-B2
View DetailsMethod for detecting nucleic acids by promoting branched DNA complex formation
US-9868983-B2
View DetailsSystem for integrated analysis of real-time polymerase chain reaction and DNA chip and method for integrated analysis using the same
US-9551038-B2
View Details
Probe system for real-time quantitative and qualitative analysis of biomaterial, reaction chamber with said probe system, and analysis method thereof
US-10428372-B2
View DetailsMethod of quantitatively and qualitatively analyzing biomaterial in real-time
US-10364459-B2
View DetailsMethod for detecting nucleic acids by promoting branched DNA complex formation
US-9868983-B2
View DetailsSystem for integrated analysis of real-time polymerase chain reaction and DNA chip and method for integrated analysis using the same
US-9551038-B2
View DetailsProducts
S-Blot 3 Plus (multiplex immunoblot system)
Automated multiplex immunoblot system for high-throughput allergy and autoantibody testing with integrated strip processing and analysis.
INCLIX F-100 (POCT analyzer with TRF)
Point-of-care analyzer employing time-resolved fluorescence detection for quantitative measurement of biomarkers from small-volume clinical samples.
Lateral-flow rapid tests (infectious disease and reproductive health panels)
Lateral-flow immunochromatographic rapid tests for infectious diseases (e.g., COVID-19, influenza) and consumer reproductive health tests (pregnancy, ovulation, menopause).
Digital/home diagnostic platforms (Surearly SMART series)
Mobile app-linked diagnostic platforms for home use that analyze urinary or small-volume samples and provide pattern analysis for hormone monitoring and chronic disease management.
Molecular diagnostic assays and integrated PCR/DNA-chip platforms
RT-PCR based assays and an integrated amplification/hybridization platform for pathogen detection and multiplex molecular diagnostics.
Diagnostic reagent panels (allergy, autoimmunity, hormone, metabolic markers)
Reagent kits and panels for allergy screening (>100 allergen targets), autoantibodies (e.g., anti-GAD for type 1 diabetes), hormone panels and other clinical biomarkers.
S-Blot 3 Plus (multiplex immunoblot system)
Automated multiplex immunoblot system for high-throughput allergy and autoantibody testing with integrated strip processing and analysis.
INCLIX F-100 (POCT analyzer with TRF)
Point-of-care analyzer employing time-resolved fluorescence detection for quantitative measurement of biomarkers from small-volume clinical samples.
Lateral-flow rapid tests (infectious disease and reproductive health panels)
Lateral-flow immunochromatographic rapid tests for infectious diseases (e.g., COVID-19, influenza) and consumer reproductive health tests (pregnancy, ovulation, menopause).
Digital/home diagnostic platforms (Surearly SMART series)
Mobile app-linked diagnostic platforms for home use that analyze urinary or small-volume samples and provide pattern analysis for hormone monitoring and chronic disease management.
Molecular diagnostic assays and integrated PCR/DNA-chip platforms
RT-PCR based assays and an integrated amplification/hybridization platform for pathogen detection and multiplex molecular diagnostics.
Diagnostic reagent panels (allergy, autoimmunity, hormone, metabolic markers)
Reagent kits and panels for allergy screening (>100 allergen targets), autoantibodies (e.g., anti-GAD for type 1 diabetes), hormone panels and other clinical biomarkers.
Services
GMP-compliant manufacture of in vitro diagnostic reagents and devices with ISO13485 and MDSAP-aligned quality systems; supports large-volume production and export.
Support for regulatory submissions and approvals for national and international markets including CE, FDA and other country-level registrations.
Joint development of diagnostic assays and devices, including antibody reagent development, assay optimization and platform integration with academic and research partners.
Deployment and integration of mobile app-based diagnostic platforms for home testing, data storage, pattern analysis and connectivity to remote clinical services.
GMP-compliant manufacture of in vitro diagnostic reagents and devices with ISO13485 and MDSAP-aligned quality systems; supports large-volume production and export.
Support for regulatory submissions and approvals for national and international markets including CE, FDA and other country-level registrations.
Joint development of diagnostic assays and devices, including antibody reagent development, assay optimization and platform integration with academic and research partners.
Deployment and integration of mobile app-based diagnostic platforms for home testing, data storage, pattern analysis and connectivity to remote clinical services.
Expertise Areas
- In vitro diagnostics (IVD) development
- Multiplex immunoblot and allergy diagnostics
- Point-of-care testing (POCT) device development
- Digital health and mobile diagnostics
Key Technologies
- Multiplex immunoblotting
- Lateral-flow immunochromatography (lateral flow assays)
- Time-resolved fluorescence (TRF) detection
- Gold nanoparticle labeling
News & Updates
SUGENTECH at MEDICA 2022
Showcasing new products including TRF-based POCT system and digital health platforms at the world's largest medical trade fair in Germany.
SUGENTECH wins Korea Electronics Show Innovation Award 2022
Awarded for its innovative digital healthcare platform Surearly SMART Pro.
SUGENTECH develops Monkeypox molecular diagnostic product
Developing RT-PCR based diagnostic test for Monkeypox detection, responding to global health threats.
SUGENTECH obtains MDSAP certification
Achieving international certification for medical device quality management, accelerating global expansion.
SUGENTECH's 3Q 2022 financial results
Recorded 99.5 billion KRW in sales and 50.4 billion KRW in operating profit, with growth in allergy, on-site, and self-diagnosis sectors.
SUGENTECH's COVID-19 self-test kit approved in Canada
The self-test kit for COVID-19 has received approval from the Canadian health authorities, expanding its global reach.
SUGENTECH at MEDICA 2022
Showcasing new products including TRF-based POCT system and digital health platforms at the world's largest medical trade fair in Germany.
SUGENTECH wins Korea Electronics Show Innovation Award 2022
Awarded for its innovative digital healthcare platform Surearly SMART Pro.
SUGENTECH develops Monkeypox molecular diagnostic product
Developing RT-PCR based diagnostic test for Monkeypox detection, responding to global health threats.
SUGENTECH obtains MDSAP certification
Achieving international certification for medical device quality management, accelerating global expansion.
SUGENTECH's 3Q 2022 financial results
Recorded 99.5 billion KRW in sales and 50.4 billion KRW in operating profit, with growth in allergy, on-site, and self-diagnosis sectors.
SUGENTECH's COVID-19 self-test kit approved in Canada
The self-test kit for COVID-19 has received approval from the Canadian health authorities, expanding its global reach.